Stocklytics Platform
Asset logo for symbol LRMR
Larimar Therapeutics
LRMR51
$7.74arrow_drop_down5.65%-$0.46
Asset logo for symbol LRMR
LRMR51

$7.74

arrow_drop_down5.65%
Key Stats
Open$8.47
Prev. Close$8.46
EPS-1.22
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.07
8.79
52 Week Range2.18
13.68
Ratios
Revenue-
EBITDA Margin %-
EPS-1.22
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.95%
Last Dividend pay dateMay 29, 2020
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

LRMR-
US Healthcare Sector-
US Market-
warning

LRMR / Market

LRMR lose to the US Market which returned 0.39% over the last twenty four hours.
warning

LRMR / Healthcare Sector

LRMR lose to the US Healthcare sector which returned 3.96% over the last twenty four hours.

Larimar Therapeutics (LRMR) Statistics

Larimar Therapeutics, Inc. (LRMR) is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare genetic disorders. The company is dedicated to improving the lives of patients and their families by addressing the underlying causes of these devastating diseases. With a strong pipeline of promising drug candidates, Larimar Therapeutics is well positioned for future growth and success.
When looking at LRMR's valuation metrics, it is clear that the market has recognized the potential of this company. With a market capitalization of [INSERT MARKET CAP], LRMR is valued at a level that reflects investor confidence in the strength of its product portfolio and its ability to bring innovative treatments to market. The stock has shown impressive performance compared to its sector, with a [INSERT STOCK PERFORMANCE VS SECTOR] return over the past year.
add Larimar Therapeutics to watchlist

Keep an eye on Larimar Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How much debt does Larimar Therapeutics (LRMR) have?

Larimar Therapeutics (LRMR) has a total debt of $5.6M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$29.7M.
help

What is the EBITDA of Larimar Therapeutics (LRMR) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Larimar Therapeutics (LRMR) is -$65.51M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How has Larimar Therapeutics (LRMR) stock's performance compared to its sector and the market over the past year?

Over the past year, Larimar Therapeutics (LRMR) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 32.99%, Larimar Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 75.68%, it has fallen short of the market average. This comparison highlights Larimar Therapeutics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Larimar Therapeutics (LRMR) stock?

The PE ratio for Larimar Therapeutics (LRMR) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Larimar Therapeutics (LRMR) stock?

The Earnings Per Share (EPS) for Larimar Therapeutics (LRMR), calculated on a diluted basis, is -$1.12. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Larimar Therapeutics (LRMR) stock?

The operating margin for Larimar Therapeutics (LRMR) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level